company background image

Genus LSE:GNS Stock Report

Last Price


Market Cap







25 Sep, 2022


Company Financials +
GNS fundamental analysis
Snowflake Score
Future Growth4/6
Past Performance2/6
Financial Health4/6

GNS Stock Overview

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.

Genus Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genus
Historical stock prices
Current Share PriceUK£27.30
52 Week HighUK£57.35
52 Week LowUK£21.86
1 Month Change7.90%
3 Month Change7.82%
1 Year Change-51.03%
3 Year Change-4.55%
5 Year Change30.12%
Change since IPO1,922.22%

Recent News & Updates

Sep 11
Genus' (LON:GNS) Dividend Will Be £0.217

Genus' (LON:GNS) Dividend Will Be £0.217

The board of Genus plc ( LON:GNS ) has announced that it will pay a dividend on the 9th of December, with investors...

Sep 09
A Look At The Fair Value Of Genus plc (LON:GNS)

A Look At The Fair Value Of Genus plc (LON:GNS)

How far off is Genus plc ( LON:GNS ) from its intrinsic value? Using the most recent financial data, we'll take a look...

Shareholder Returns

GNSGB BiotechsGB Market

Return vs Industry: GNS underperformed the UK Biotechs industry which returned -40.8% over the past year.

Return vs Market: GNS underperformed the UK Market which returned -14.4% over the past year.

Price Volatility

Is GNS's price volatile compared to industry and market?
GNS volatility
GNS Average Weekly Movement7.5%
Biotechs Industry Average Movement7.5%
Market Average Movement5.3%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: GNS is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: GNS's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

19943,400Stephen Wilson

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.

Genus Fundamentals Summary

How do Genus's earnings and revenue compare to its market cap?
GNS fundamental statistics
Market CapUK£1.78b
Earnings (TTM)UK£40.90m
Revenue (TTM)UK£593.40m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GNS income statement (TTM)
Cost of RevenueUK£0
Gross ProfitUK£593.40m
Other ExpensesUK£552.50m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)0.63
Gross Margin100.00%
Net Profit Margin6.89%
Debt/Equity Ratio33.1%

How did GNS perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio

Does GNS pay a reliable dividends?

See GNS dividend history and benchmarks
When do you need to buy GNS by to receive an upcoming dividend?
Genus dividend dates
Ex Dividend DateNov 17 2022
Dividend Pay DateDec 09 2022
Days until Ex dividend51 days
Days until Dividend pay date73 days

Does GNS pay a reliable dividends?

See GNS dividend history and benchmarks
We’ve recently updated our valuation analysis.


Is GNS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GNS?

Other financial metrics that can be useful for relative valuation.

GNS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.3x
Enterprise Value/EBITDA24.5x
PEG Ratio1.7x

Price to Earnings Ratio vs Peers

How does GNS's PE Ratio compare to its peers?

GNS PE Ratio vs Peers
The above table shows the PE ratio for GNS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average15.1x
BVXP Bioventix
INDV Indivior
HIK Hikma Pharmaceuticals
GNS Genus

Price-To-Earnings vs Peers: GNS is expensive based on its Price-To-Earnings Ratio (43.5x) compared to the peer average (15.1x).

Price to Earnings Ratio vs Industry

How does GNS's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Earnings vs Industry: GNS is expensive based on its Price-To-Earnings Ratio (43.5x) compared to the European Biotechs industry average (34x)

Price to Earnings Ratio vs Fair Ratio

What is GNS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.5x
Fair PE Ratio43.5x

Price-To-Earnings vs Fair Ratio: GNS is good value based on its Price-To-Earnings Ratio (43.5x) compared to the estimated Fair Price-To-Earnings Ratio (43.5x).

Share Price vs Fair Value

What is the Fair Price of GNS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GNS (£27.3) is trading below our estimate of fair value (£28.3)

Significantly Below Fair Value: GNS is trading below fair value, but not by a significant amount.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Genus forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score


Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNS's forecast earnings growth (25.4% per year) is above the savings rate (0.9%).

Earnings vs Market: GNS's earnings (25.4% per year) are forecast to grow faster than the UK market (8.9% per year).

High Growth Earnings: GNS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GNS's revenue (7.7% per year) is forecast to grow faster than the UK market (4.5% per year).

High Growth Revenue: GNS's revenue (7.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GNS's Return on Equity is forecast to be low in 3 years time (9.9%).

Discover growth companies

Past Performance

How has Genus performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GNS has high quality earnings.

Growing Profit Margin: GNS's current net profit margins (6.9%) are lower than last year (8.2%).

Past Earnings Growth Analysis

Earnings Trend: GNS's earnings have grown by 2.9% per year over the past 5 years.

Accelerating Growth: GNS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GNS had negative earnings growth (-13.5%) over the past year, making it difficult to compare to the Biotechs industry average (-15.8%).

Return on Equity

High ROE: GNS's Return on Equity (6.4%) is considered low.

Discover strong past performing companies

Financial Health

How is Genus's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: GNS's short term assets (£257.5M) exceed its short term liabilities (£151.3M).

Long Term Liabilities: GNS's short term assets (£257.5M) do not cover its long term liabilities (£294.5M).

Debt to Equity History and Analysis

Debt Level: GNS's net debt to equity ratio (26.3%) is considered satisfactory.

Reducing Debt: GNS's debt to equity ratio has reduced from 33.5% to 33.1% over the past 5 years.

Debt Coverage: GNS's debt is not well covered by operating cash flow (18.1%).

Interest Coverage: GNS's interest payments on its debt are well covered by EBIT (9.4x coverage).

Balance Sheet

Discover healthy companies


What is Genus's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Upcoming Dividend Payment

TodaySep 26 2022Ex Dividend DateNov 17 2022Dividend Pay DateDec 09 202222 days from Ex DividendBuy in the next 51 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: GNS's dividend (1.17%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (2.06%).

High Dividend: GNS's dividend (1.17%) is low compared to the top 25% of dividend payers in the UK market (5.81%).

Stability and Growth of Payments

Stable Dividend: GNS's dividend payments have been volatile in the past 10 years.

Growing Dividend: GNS's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (51.2%), GNS's dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: GNS is paying a dividend but the company has no free cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Stephen Wilson (62 yo)





Mr. Stephen Wilson serves as Independent Non-Executive Director of Renishaw plc since June 01, 2022. He has extensive business leadership experience, including strategic, financial and business development...

CEO Compensation Analysis

Compensation vs Market: Stephen's total compensation ($USD3.16M) is above average for companies of similar size in the UK market ($USD2.16M).

Compensation vs Earnings: Stephen's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

Leadership Team

Experienced Management: GNS's management team is seasoned and experienced (5.4 years average tenure).

Board Members

Experienced Board: GNS's board of directors are considered experienced (4.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

LSE:GNS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Jul 22BuyUK£1,150,000Devon Equity Management LimitedCompany50,000UK£23.00
24 Nov 21BuyUK£224,016Iain G. FergusonIndividual5,000UK£44.96
24 Nov 21BuyUK£94,227Stephen WilsonIndividual2,000UK£47.11
13 Oct 21SellUK£336,203William ChristiansonIndividual6,203UK£54.20
12 Oct 21SellUK£188,179Stephen WilsonIndividual3,564UK£52.80
12 Oct 21SellUK£50,482Dan HartleyIndividual957UK£52.75

Ownership Breakdown

What is the ownership structure of GNS?
Owner TypeNumber of SharesOwnership Percentage
State or Government22,8190.04%
Private Companies74,7790.1%
Employee Share Scheme130,2050.2%
Individual Insiders186,5650.3%
General Public12,298,82718.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 64.62% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Capital Research and Management Company
Baillie Gifford & Co.
Columbia Management Investment Advisers, LLC
Wellington Management Group LLP
The Vanguard Group, Inc.
2,990,834£81.6m-0.41%no data
abrdn plc
Legal & General Investment Management Limited
Royal London Asset Management Limited
Jupiter Fund Management Plc
T. Rowe Price Group, Inc.
1,306,703£35.7m-0.02%no data
Ignis Investment Services Limited
Norges Bank Investment Management
1,122,633£30.6m0%no data
Devon Equity Management Limited
Credit Suisse, Investment Banking and Securities Investments
N.F.U. Mutual Unit Managers Limited
Lansdowne Partners Limited
Comgest S.A.
State Street Global Advisors, Inc.
663,683£18.1m7.76%no data
HSBC Global Asset Management (UK) Limited
J.M. Finn & Co. Ltd.
Bayberry Capital Partners LP
AXA Investment Managers S.A.
Schroder Investment Management Limited
BNY Mellon Asset Management
446,800£12.2m3.4%no data
Rathbone Investment Management Limited

Company Information

Genus plc's employee growth, exchange listings and data sources

Key Information

  • Name: Genus plc
  • Ticker: GNS
  • Exchange: LSE
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: UK£1.779b
  • Shares outstanding: 65.17m
  • Website:

Number of Employees


  • Genus plc
  • Matrix House
  • Basing View
  • Basingstoke
  • Hampshire
  • RG21 4DZ
  • United Kingdom


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNSLSE (London Stock Exchange)YesOrdinary SharesGBGBPJan 1998
GENS.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1998
GBEDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1998
GNSLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPJan 1998

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/25 00:00
End of Day Share Price2022/09/23 00:00
Annual Earnings2022/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.